MKI-1

Research use only, not for human use.

MKI-1 (MASTL Kinase Inhibitor-1) is an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like, IC50= 9.9 μM).

MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.

MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells.MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells.MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation.MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells.Western Blot Analysis Cell Line:MCF7 and T47D cells.Concentration:5-20 μM. Incubation Time:24 h.Result:Inhibited the phosphorylation of ENSA in MCF7 and T47D cells.Significantly inhibited the phosphorylation of ENSA in mitotic cells.

MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice.Animal Model:Five-week-old female BALB/c nude mice (BT549 cells).Dosage:50 mg/kg.Administration:Twice per week by intraperitoneal (i.p.) injection.Result:Reduced tumor growth.

——

Others

Other Targets

Others

——

——

1190277-80-5

302.33

C18H14N4O

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (826.91 mM; Ultrasonic )

O=C(Nc1nc2ccccc2[nH]1)c1cccc(c1)-n1cccc1

——

(-20℃)

With Ice Pack

≥ 2 years